Brief: Sino Biopharmaceutical Updates On Phase III Registrational Clinical Study Of TQB2868 Injection
10/06/2025 11:28
June 10 (Reuters) - Sino Biopharmaceutical Ltd 1177.HK: CDE APPROVAL TO INITIATE PHASE III REGISTRATIONAL CLINICAL STUDY OF TQB2868 INJECTION PD-1/TGF- BI-FUNCTIONAL FUSION PROTEIN Further company coverage: 1177.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sino Biopharmaceutical
See all newsBrief: Sino Biopharmaceutical Announces Share Purchase Plan For HK$2 Billion
Brief: Sino Biopharmaceutical Says Marketing Application For M701 Accepted By China In May 2026
Brief: Sino Biopharmaceutical Says Zongertinib Approved By NMPA China
GSK to team up with Sino Biopharma for China launch of hepatitis B treatment (updated)
HK-listed Sino Biopharmaceutical hits 2-week high on GSK tie-up